CDC provides $12.5m grant to study real-world effectiveness of vaccines

pharmafile | December 16, 2022 | News story | Research and Development  

The Center for Disease Control and Prevention (CDC) has given researchers at Washington University School of Medicine in St Louis, US a $12.5m grant, allowing them to assess the real-world effectiveness of influenza and COVID-19 vaccines as well as the immune response to both infection and vaccination against the two illnesses.

The research is intended to understand how vaccination strategies work for real people living in the real-world in which they may not receive their vaccines and boosters on a strict timeframe and may not receive all doses from the same vaccine maker. Clearly this differs somewhat from a highly controlled clinical trial.

There will be seven sites involved in this study, including the School of Medicine. Others include the University of Michigan, Baylor Scott & White Health, Kaiser Permanente Washington, the University of Pittsburgh, University Hospitals Cleveland and Arizona State University, all US. Duke University is also involved as the study’s coordinating centre.

The study aims to enrol at least 5,000 participants over a five-year timeframe. Both adult and paediatric patients with respiratory tract infections will be tested for both the flu and COVID-19: the researchers will then collect patients’ data, including medical and vaccine history, and assess the patients over time.

Stacey L House, MD, PhD, and principal investigator on the study, commented: “We want to understand how these vaccines work in the real world. […] These vaccines have proven to be effective in clinical trials. But we don’t know what it means for the immune response if second doses are delayed, or if boosters are taken at vastly different times, or if people switch vaccine manufacturers for their third or fourth dose, for example. By enrolling large numbers of patients and gathering many data points about them, we hope to understand how effective vaccines are in a diverse community.”


Betsy Goodfellow

Related Content

No items found

Latest content